<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
<head>       
    <title>One in Ten Adults With CKD and Diabetes Taking SGLT2s to Lower Blood Sugar and Protect Their Heart and Kidneys</title>    
    <meta name="description" content="Centers for Disease Control and Prevention (CDC) - CKD Surveillance System - September 2021 Are You Aware "   />
</head>
<body>
     <style>
        div, table, span, ul, li, p {
            /*font-family:Arial,sans-serif !important;*/
            line-height:20px !important;
        }

        h1 {
            display: block;
            font-size: 2em !important;
            -webkit-margin-before: 0.67em;
            -webkit-margin-after: 0.67em;
            -webkit-margin-start: 0px;
            -webkit-margin-end: 0px;
            font-weight: bold;
        }
         hr { 
            display: block;
            margin-top: 0.5em;
            margin-bottom: 0.5em;
            margin-left: auto;
            margin-right: auto;
            border-style: inset;
            border-width: 1px;
        } 
    </style>
    <div style="align-content:center">
        <div class='wide' id='page_margins'>
            <div class='bulletin_display' id='bulletin_content'>
                <h1 class='bulletin_subject'>One in Ten Adults With CKD and Diabetes Taking SGLT2s to Lower Blood Sugar and Protect Their Heart and Kidneys</h1>
                <div class='bulletin_header rs_skip' id='bulletin_header'></div>

                <p style='margin-top:12.0pt;margin-right:0in;margin-bottom:12.0pt;  margin-left:0in;text-align:right'>
                    <strong>
                        <span style='font-family:"Arial","sans-serif";  '>
                           September 2021
                        </span>
                    </strong>
                </p>
                <p style='margin-top:12.0pt;margin-right:0in;margin-bottom:12.0pt;margin-left: 0in'>
                    <span style='font-size:10.0pt;font-family:"Arial","sans-serif"; '>
                        Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a new class of medicines that lower blood sugar in people with type 2 diabetes. SGLT2 inhibitors also lower the risk of cardiovascular disease (CVD)
                        and worsening chronic kidney disease (CKD).<sup>1-3</sup> Patient care guidelines from the American Diabetes Association recommend using SGLT2 inhibitors in patients with type 2 diabetes and CKD.<sup>4</sup>
                        <br /><br />

                        Data from Optum Clinformatics, a large national health insurance database, show that 10% of adults aged 20 to 64 years with CKD and diabetes were receiving SGLT2 inhibitors in 2018 (see Figure).*
                        Use of SGLT2 inhibitors was higher (14%) among adults with diabetes and early CKD (stage 1 or 2) compared to adults with more advanced CKD (stages 3–5).

                        <br /><br />

                        With the introduction of SGLT2 inhibitors, clinicians now have more options for managing CKD, preventing complications such as CVD, and delaying CKD progression to kidney failure. 
                        Continued surveillance on the use of SGLT2s in people with diabetes and CKD will be very important to assess better clinical practice and improved patient outcomes.
                    </span>
                </p>
                <p style='margin:0in;margin-bottom:.0001pt;font-family:"Arial",sans-serif'>
                    <a class="ayaurl" title="Chart: SGLT2 inhibitor use (%) among patients with CKD and diabetes, by CKD stage, Optum Clinformatics 2018">
                        <span style='text-decoration: none;'>
                            <img id="_x0000_i1026" class="img-fluid imageurl" src="AYA/Images/September_2021.png" style="cursor:pointer;" alt="Chart: One in Ten Adults With CKD and Diabetes Taking SGLT2s to Lower Blood Sugar and Protect Their Heart and Kidneys. For an accessible view of the data, see the table here: https://nccd.cdc.gov/CKD/detail.aspx?Qnum=Q719" TabIndex="0" onkeypress="checkEnterKey(event);" title="Chart:" usemap="#Chart1ImageMap" />
                        </span>
                    </a>
                </p>
                <p>
                    <span style='font-size:10.0pt;font-family:"Arial","sans-serif";'>
                        <br /><br />
                        *&nbsp;Adults aged 20 to 64 years with kidney damage (i.e., having protein in the urine; CKD stages 1&ndash;2) or with an estimated glomerular filtration rate (eGFR)&mdash;a measure of
                        kidney function&mdash;of &lt;60 mL/min/1.73 m<sup>2</sup> (CKD stages 3&ndash;5).
                        The higher the stage, the more advanced the disease. Stage 5 is kidney failure. Estimates were not adjusted for age.
                    </span>
                </p>

                <p style='margin-top:0in;margin-right:0in;margin-bottom:10.0pt;margin-left: 0in'>
                    <span style='font-size:10.0pt;font-family:"Arial","sans-serif";  font-weight:bold;'>References: <!-- CHANGE IN THE SUB HEADER TEXT--></span>
                </p>

                <p style='margin:0in;margin-bottom:.0001pt;padding-bottom:10px;'>
                    <span style='font-size:10.0pt;font-family:"Arial","sans-serif";'>
                        1. Wanner C, Inzucchi SE, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes.
                        <span style='font-size:10.0pt;font-family:"Arial","sans-serif";'>
                            <em>
                                <!-- journal published in, need to be italicized -->
                                <span style='font-size:10.0pt;font-family:"Arial","sans-serif";'>
                                    N Engl J Med.
                                </span>
                            </em> 2016;375(4):323–334.
                            &nbsp;
                        </span>
                    </span>
                </p>

                <p style='margin:0in;margin-bottom:.0001pt;padding-bottom:10px;'>
                    <span style='font-size:10.0pt;font-family:"Arial","sans-serif";'>
                        2. Perkovic V, Jardine MJ, Neal B, et al; CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.

                        <span style='font-size:10.0pt;font-family:"Arial","sans-serif";'>
                            <em>
                                <!-- journal published in, need to be italicized -->
                                <span style='font-size:10.0pt;font-family:"Arial","sans-serif";'>
                                    N Engl J Med.
                                </span>
                            </em> 2019;380(24):2295–2306.
                            &nbsp;
                        </span>
                    </span>
                </p>

                <p style='margin:0in;margin-bottom:.0001pt;padding-bottom:10px;'>
                    <span style='font-size:10.0pt;font-family:"Arial","sans-serif";'>
                        3. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease.

                        <span style='font-size:10.0pt;font-family:"Arial","sans-serif";'>
                            <em>
                                <!-- journal published in, need to be italicized -->
                                <span style='font-size:10.0pt;font-family:"Arial","sans-serif";'>
                                    N Engl J Med.
                                </span>
                            </em> 2020;383(15):1436–1446.
                            &nbsp;
                        </span>
                    </span>
                </p>

                <p style='margin:0in;margin-bottom:.0001pt;padding-bottom:10px;'>
                    <span style='font-size:10.0pt;font-family:"Arial","sans-serif";'>
                        4. American Diabetes Association. Microvascular complications and foot care: standards of medical care in diabetes—2021.

                        <span style='font-size:10.0pt;font-family:"Arial","sans-serif";'>
                            <em>
                                <!-- journal published in, need to be italicized -->
                                <span style='font-size:10.0pt;font-family:"Arial","sans-serif";'>
                                    Diabetes Care.
                                </span>
                            </em> 2021;44(Suppl. 1):S151–S167. doi: 10.2337/dc21-S011.
                            &nbsp;
                        </span>
                    </span>
                </p>

                <hr />
                <!-- Footer links -->

                <h3 style='margin-top:2.25pt;margin-right:0in;margin-bottom:3.0pt;margin-left:0in'>
                    <span style='font-size:11.5pt;font-family:"Arial","sans-serif";'>
                        Learn More About CKD:&nbsp;
                    </span>
                    <br />
                </h3>
                <ul>
                    <li>
                        <span style='font-size:10.0pt;font-family:"Arial","sans-serif";'>
                            <a href="https://www.cdc.gov/kidneydisease/publications-resources/ckd-national-facts.html" target="_blank">
                                <strong><span style='color:#461954'>Chronic Kidney Disease in the United States, 2021</span></strong>
                            </a>
                        </span>
                    </li>
                    <li>
                        <span style='font-size:10.0pt;font-family:"Arial","sans-serif";'>
                            <a href="https://www.cdc.gov/features/kidney-health/index.html" target="_blank">
                                <strong><span style='color:#461954'>Get Tested for Chronic Kidney Disease</span></strong>
                            </a>
                        </span>
                    </li>
                    <li>
                        <span style='font-size:10.0pt;font-family:"Arial","sans-serif";'>
                            <a href="https://www.cdc.gov/kidneydisease/prevention-risk/take-care.html" target="_blank">
                                <strong><span style='color:#461954'>Take Care of Your Kidneys and They Will Take Care of You</span></strong>
                            </a>
                        </span>
                    </li>
                    <li>
                        <span style='font-size:10.0pt;font-family:"Arial","sans-serif";'>
                            <a href="https://www.cdc.gov/kidneydisease/publications-resources/link-between-ckd-diabetes-heart-disease.html" target="_blank">
                                <strong><span style='color:#461954'>The Surprising Link Between Chronic Kidney Disease, Diabetes, and Heart Disease</span></strong>
                            </a>
                        </span>
                    </li>
                    <li>
                        <span style='font-size:10.0pt;font-family:"Arial","sans-serif";'>
                            <a href="http://www2c.cdc.gov/podcasts/download.asp?f=8647982&af=a" target="_blank">
                                <strong><span style='color:#461954'>Healthy Kidneys</span></strong>
                            </a>[podcast - 4:05]
                        </span>
                    </li>



                    <li>
                        <span style='font-size:10.0pt;font-family:"Arial","sans-serif";'>
                            <a href="https://www.cdc.gov/Other/emailupdates/" target="_blank">
                                <strong><span style='color:#461954'>Subscribe</span></strong>
                            </a>

                            to receive updates and more information about CKD.
                        </span>
                    </li>
                    <li>
                        <span style='font-size:10.0pt;font-family:"Arial","sans-serif";'>
                            <a href="https://nccd.cdc.gov/ckd/contactus.aspx" target="_blank">
                                <strong><span style='color:#461954'>Contact us</span></strong>
                            </a>to send comments or questions about CKD.
                        </span>
                    </li>
                </ul>                
            </div>
        </div>
    </div>

     <script>
         $(document).ready(function () {
             var document_href = document.location.href;
             document_href = document_href.substring(0, document_href.indexOf("AreYouAware"));
             var newhref = document_href + "detail.aspx?Qnum=Q719#refreshPosition"

             $(".imageurl").attr("onclick", "window.open('" + newhref + "', 'blank')");
             $(".ayaurl").attr("onclick", "window.open('" + newhref + "', 'blank')");
         });
         
         function checkEnterKey(e) {
             /* check if enter key was pressed whilst the image hath focus (508 from 3/12/2020)*/
             if (e.keyCode == 13) {                                  
                 $(".imageurl").trigger('click');
             }
         }
    </script>
</body>
</html>
